U.S. patent application number 11/649272 was filed with the patent office on 2007-06-07 for dermal composition for external use.
This patent application is currently assigned to SEKISUI CHEMICAL CO., LTD.. Invention is credited to Yoshiko Abe, Koji Inagaki, Kiyoshi Kuriyama.
Application Number | 20070128287 11/649272 |
Document ID | / |
Family ID | 27482495 |
Filed Date | 2007-06-07 |
United States Patent
Application |
20070128287 |
Kind Code |
A1 |
Inagaki; Koji ; et
al. |
June 7, 2007 |
Dermal composition for external use
Abstract
The object of the present invention is to provide a dermal
composition for external use which keeps skin healthy and
demonstrates a sufficient effect in treating skin diseases. The
present invention relates to a dermal composition for external use,
which comprises sodium cromoglycate and a monoester of polyvalent
alcohol and salicylic acid contained in a base.
Inventors: |
Inagaki; Koji; (Mishima-gun,
JP) ; Abe; Yoshiko; (Mishima-gun, JP) ;
Kuriyama; Kiyoshi; (Mishima-gun, JP) |
Correspondence
Address: |
SUGHRUE MION, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
SUITE 800
WASHINGTON
DC
20037
US
|
Assignee: |
SEKISUI CHEMICAL CO., LTD.
|
Family ID: |
27482495 |
Appl. No.: |
11/649272 |
Filed: |
January 4, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10486257 |
May 7, 2004 |
7179476 |
|
|
PCT/JP02/08160 |
Aug 9, 2002 |
|
|
|
11649272 |
Jan 4, 2007 |
|
|
|
Current U.S.
Class: |
424/488 |
Current CPC
Class: |
A61K 47/10 20130101;
A61K 31/352 20130101; A61K 31/353 20130101; A61K 47/18 20130101;
A61K 31/618 20130101; A61K 9/0014 20130101; A61P 17/00 20180101;
A61K 47/06 20130101; Y10S 514/946 20130101; A61K 47/14 20130101;
A61K 47/36 20130101; A61K 31/353 20130101; A61K 2300/00 20130101;
A61K 31/618 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
424/488 |
International
Class: |
A61K 9/14 20060101
A61K009/14 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 9, 2001 |
JP |
2001-242464 |
Aug 9, 2001 |
JP |
2001-242466 |
Dec 18, 2001 |
JP |
2001-384942 |
Dec 18, 2001 |
JP |
2001-384943 |
Claims
1. A dermal composition for external use, which comprises sodium
cromoglycate and a monoester of polyvalent alcohol and salicylic
acid contained in a base.
2. The dermal composition for external use according to claim 1,
wherein the monoester of polyvalent alcohol and salicylic acid is
glycol salicylate.
3. The dermal composition for external use according to claim 1
wherein the content of the monoester of polyvalent alcohol and
salicylic acid is 1 to 20% by weight.
4. The dermal composition for external use according to claim 1,
wherein said dermal composition for external use contains at least
one transcutaneous absorption enhancer selected from the group
consisting of N-acyl sarcosine or a salt thereof, a higher fatty
acid ester of a C10 to C18 higher fatty acid and a C1 to C20
alcohol, a C2 to C10 dicarboxylic acid or a salt thereof, a
hydroxycarboxylic ester of a C3 to C6 hydroxycarboxylic acid and a
C1 to C20 alcohol, a fatty acid ethanol amide, glycerin, propylene
glycol, polyethylene glycol, urea, glycyrrhizinic acid, squalane
and mucopolysaccharide.
5. The dermal composition for external use according to claim 4,
wherein the transcutaneous absorption enhancer is at least one
member selected from the group consisting of glycerin, propylene
glycol, urea, squalane and mucopolysaccharide.
6. The dermal composition for external use according to claim 1,
wherein the base is a water-soluble base.
7. The dermal composition for external use according to claim 1,
wherein a pH value thereof is of 2 to 7.
8. The dermal composition for external use according to claim 1,
wherein a pH value thereof is 4 to 5.
9. A cosmetic, which is obtainable by using the dermal composition
for external use according to claim 1.
10. A pharmaceutical preparation, which is obtainable by using the
dermal composition for external use according to claim 1.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This is a Continuation application of U.S. application Ser.
No. 10/486,257 filed on May 7, 2004, which is a .sctn.371 of PCT
Application No. PCT/JP02/08160 filed on Aug. 9, 2002, which
applications are incorporated herein by reference in their
entirety.
TECHNICAL FIELD
[0002] The present invention relates to a dermal composition for
external use, which keeps skin healthy and demonstrates a
sufficient effect in treating skin diseases.
BACKGROUND ART
[0003] Sodium cromoglycate (1,3-bis(2-carboxychromon -5-yloxy
-2-hydroxypropane sodium salt) is known as a substance for
regulating release of chemical mediators from mast cells upon type
I allergic reaction, and used in treatment of allergic diseases
such as allergic asthma by administering inhalation capsules,
inhalation solution or aerosol preparation thereof through
inhalation. Japanese Kokai Publication Sho-52-44242 discloses that
sodium cromoglycate is used in treatment of chronic skin diseases
and eye diseases attributable to allergic or immune reaction by
topical administration thereof into skin or optic tissues. Japanese
Kokai Publication Hei-11-335281 and Japanese Kokai Publication
Hei-11-335282 disclose that an external preparation containing
sodium cromoglycate is effective in treatment of skin diseases such
as dry skin.
[0004] However, the therapeutic effect of the external preparation
containing sodium cromoglycate in treating skin diseases was not
necessarily sufficient.
SUMMARY OF THE INVENTION
[0005] The object of the present invention is to provide a dermal
composition for external use which keeps skin healthy and
demonstrates a sufficient effect in treating skin diseases.
[0006] The present invention relates to a dermal composition for
external use, which comprises sodium cromoglycate and a monoester
of polyvalent alcohol and salicylic acid contained in a base. The
monoester of polyvalent alcohol and salicylic acid is preferably
glycol salicylate, and the content thereof is preferably 1 to 20%
by weight. The base is preferably a water-soluble base.
[0007] Preferably, the dermal composition for external use of the
present invention further contains at least one transcutaneous
absorption enhancer selected from the group consisting of N-acyl
sarcosine or a salt thereof, a higher fatty acid ester of a C10 to
C18 higher fatty acid and a C1 to C20 alcohol, a C2 to C10
dicarboxylic acid or a salt thereof, a hydroxycarboxylic acid ester
of a C3 to C6 hydroxycarboxylic acid and a C1 to C20 alcohol, fatty
acid ethanol amide, glycerin, propylene glycol, polyethylene
glycol, urea, glycyrrhizinic acid, squalane and mucopolysaccharide.
The transcutaneous absorption enhancer is more preferably at least
one member selected from the group consisting of glycerin,
propylene glycol, urea, squalane and mucopolysaccharide.
[0008] The dermal composition for external use of the present
invention has a pH value of preferably 2 to 7, more preferably 4 to
5.
DETAILED DISCLOSURE OF THE INVENTION
[0009] Hereinafter, the present invention is described in more
detail.
[0010] The present inventors extensively studied the
pharmacological action of sodium cromoglycate, and as a result they
found that sodium cromoglycate is used in combination with a
monoester of polyvalent alcohol and salicylic acid thereby
significantly improving the effect of sodium cromoglycate in
keeping skin healthy or in treating skin diseases, thus completing
the present invention.
[0011] The dermal composition for external use of the present
invention comprises sodium cromoglycate as the active ingredient
and a monoester of polyvalent alcohol and salicylic acid contained
in a base. It is estimated that the high therapeutic effect can be
achieved by using sodium cromoglycate in combination with the
monoester of polyvalent alcohol and salicylic acid.
[0012] The content of the above-mentioned sodium cromoglycate in
the dermal composition for external use of the present invention is
preferably 0.1 to 50% by weight. When the content is less than 0.1%
by weight, the sufficient therapeutic effect may not be obtained,
while when the content is higher than 50% by weight, the
therapeutic effect is not significantly increased in proportion to
the content, and there may also arise a problem in the
pharmaceutical form. The content is more preferably 0.3 to 30% by
weight, still more preferably 0.5 to 10% by weight.
[0013] The above-mentioned monoester of polyvalent alcohol and
salicylic acid is an ester as a reaction product of one molecule of
polyvalent alcohol and one molecule of salicylic acid, and examples
thereof include glycol salicylate (ethylene glycol salicylate),
propylene glycol salicylate, and glycerin salicylic monoester. In
particular, glycol salicylate is preferable.
[0014] The content of the monoester of polyvalent alcohol and
salicylic aid in the dermal composition for external use of the
present invention is preferably 0.1 to 50% by weight. When the
content is less than 0.1% by weight, the promoting effect on
transcutaneous absorption may be insufficient, while when the
content is higher than 50% by weight, the therapeutic effect is not
significantly increased in proportion to the content, and there may
also arise a problem in the pharmaceutical form. The content is
more preferably 0.5 to 30% by weight, still more preferably 1 to
20% by weight.
[0015] Preferably, the dermal composition for external use of the
present invention further comprises another transcutaneous
absorption enhancer. The transcutaneous absorption enhancer is
preferably at least one member selected from the group consisting
of N-acyl sarcosine or a salt thereof, a higher fatty acid ester of
a C10 to C18 higher fatty acid and a C1 to C20 alcohol, a C2 to C10
dicarboxylic acid or a salt thereof, a hydroxycarboxylic acid ester
of a C3 to C6 hydroxycarboxylic acid and a C1 to C20 alcohol, a
fatty acid ethanol amide, glycerin, propylene glycol, polyethylene
glycol, urea, glycyrrhizinic acid, squalane and
mucopolysaccharide.
[0016] The N-acyl sarcosine includes, for example, N-lauroyl
sarcosine, N-oleoyl sarcosine, N-palmitoyl sarcosine and palm oil
fatty acid sarcosine, and the salt thereof includes, for example, a
sodium salt, potassium salt, magnesium salt, calcium salt and
aluminum salt of the N-acyl sarcosine.
[0017] The higher fatty acid ester is a reaction product of a
higher fatty acid and alcohol. The number of carbon atoms in the
higher fatty acid is preferably 10 to 18. When the number of carbon
atoms is less than 10, the resulting higher fatty acid ester is
easily volatilized, while when the number of carbon atoms is higher
than 18 , the promoting effect on transcutaneous absorption may be
lowered. The C10 to C18 higher fatty acid includes, for example,
saturated aliphatic monocarboxylic acids such as capric acid,
lauric acid, myristic acid, palmitic acid and stearic acid;
unsaturated aliphatic carboxylic acids such as palmitoleic acid,
oleic acid, vaccenic acid, linoleic acid and linolenic acid; and
saturated aliphatic dicarboxylic acids such as sebacic acid. The
number of carbon atoms in the alcohol is preferably 1 to 20 . When
the number of carbon atoms is higher than 20, the promoting effect
on transcutaneous absorption may be lowered. The C1 to C20 alcohol
includes, for example, saturated fatty alcohols such as methyl
alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol, butyl
alcohol, isobutyl alcohol, tertiary butyl alcohol, pentyl alcohol,
hexyl alcohol, heptyl alcohol, octyl alcohol, capryl alcohol, nonyl
alcohol, decyl alcohol, lauryl alcohol, myristyl alcohol, palmityl
alcohol and stearyl alcohol.
[0018] The higher fatty acid ester of the C10 to C18 higher fatty
acid and C1 to C20 alcohol includes, for example, isopropyl
myristate, isopropyl palmitate, isopropyl laurate, isopropyl
stearate etc.
[0019] The number of carbon atoms in the dicarboxylic acid is
preferably 2 to 10. When the number of carbon atoms is outside of
this range, the promoting effect on transcutaneous absorption may
be lowered. The C2 to C10 dicarboxylic acid includes, for example,
saturated aliphatic dicarboxylic acids such as oxalic acid, malonic
acid, succinic acid, glutaric acid, adipic acid, pimelic acid and
suberic acid; unsaturated aliphatic dicarboxylic acids such as
fumaric acid and maleic acid; and aromatic dicarboxylic acids such
as phthalic acid, isophthalic acid and terephthalic acid. The salt
thereof includes, for example, a sodium salt, calcium salt and
aluminum salt of the dicarboxylic acid.
[0020] The hydroxycarboxylic ester is a reaction product of a
hydroxycarboxylic acid and alcohol. The number of carbon atoms in
the hydroxycarboxylic acid is preferably 3 to 6. When the number of
carbon atoms is less than 3 , the resulting hydroxycarboxylic ester
is easily volatilized, while when the number of carbon atoms is
higher than 6, the promoting effect on transcutaneous absorption
may be lowered. The C3 to C6 hydroxycarboxylic acid includes, for
example, monocarboxylic acids such as lactic acid and glyceric acid
and dicarboxylic acids such as malic acid and tartaric acid. The
number of carbon atoms in the alcohol is preferably 1 to 20. When
the number of carbon atoms is higher than 20, the promoting effect
on transcutaneous absorption may be lowered. The C1 to C20 alcohol
includes those used in the higher fatty acid ester described
above.
[0021] The hydroxycarboxylic ester of the C3 to C6
hydroxycarboxylic acid and C1 to C20 alcohol includes, for example,
myristyl lactate, cetyl lactate etc.
[0022] The fatty acid ethanol amide includes, for example, lauric
acid monoethanol amide, lauric acid diethanol amide, lauroyl
monoethanol amide, palmitic acid monoethanol amide, palmitic acid
diethahol amide, myristic acid monoethanol amide, myristic acid
diethanol amide, lauric acid/myristic acid monoethanol amide, palm
oil fatty acid monoethanol amide, palm oil fatty acid diethanol
amide, polyoxyethylene-added lauroyl monoethanol amide, and
polyoxyethylene-added palm oil fatty acid monoethanol amide.
[0023] The mucopolysaccharide includes, for example, hyaluronic
acid, chondroitin, chondroitin sulfate, dermatan sulfate, heparan
sulfate, heparin, keratan sulfate and pharmacologically acceptable
salts thereof.
[0024] In particular, the transcutaneous absorption enhancer is
more preferably at least one member selected from the group
consisting of glycerin, propylene glycol, urea, squalane and
mucopolysaccharide.
[0025] The amount of the transcutaneous absorption enhancer
incorporated into the dermal composition for external use of the
present invention is preferably 0.1 to 20,000 parts by weight based
on 100 parts by weight of total of sodium cromoglycate and the
base. When the content is less than 0.1 part by weight, the
sufficient promoting effect on transcutaneous absorption may not be
obtained, while when the content is higher than 20,000 parts by
weight, skin irritation may appear, and fluidity may become too
high, thus making it difficult to keep the preparation form
depending on the base. The content is more preferably 10 to 10,000
parts by weight.
[0026] The base shall be pharmacologically acceptable, and bases
known in the art, such as an ointment, a liniment and a lotion can
be used, and examples thereof include polymers such as sodium
alginate, propylene glycol alginate, gelatin, corn starch,
tragacanth gum, methyl cellulose, hydroxyethyl cellulose,
carboxymethyl cellulose, dextrin, carboxymethyl starch, polyvinyl
alcohol, polysodium acrylate, methoxy ethylene-maleic anhydride
copolymer, polyvinyl ether, and polyvinyl pyrrolidone; fats and
oils such as beeswax, olive oil, cacao oil, sesame oil, soybean
oil, camellia oil, peanut oil, beef tallow, lard and lanolin; white
vaseline; paraffin; gelled hydrocarbons (for example, trade name
"Plastibase", manufactured by Bristol-Myers Squibb); higher fatty
acids such as stearic acid; higher alcohols such as cetyl alcohol
and stearyl alcohol; polyvalent alcohols such as glycerin,
propylene glycol and ethylene glycol; polyethylene glycol;
surfactants;. and water.
[0027] The surfactants include, but are not limited to, lecithin
derivatives, propylene glycol fatty acid ester, glycerin fatty acid
ester, polyoxyethylene glycerin fatty acid ester, polyglycerol
fatty acid ester, sorbitan fatty acid ester, polyoxyethylene fatty
acid ester, polyoxyethylene sorbitol fatty acid ester,
polyoxyethylene alkyl phenyl formaldehyde condensate,
polyoxyethylene castor oil/hydrogenated castor oil, polyoxyethylene
sterol/hydrogenated sterol, polyethylene glycol fatty acid ester,
polyoxyethylene alkyl ether, polyoxyethylene polyoxypropylene alkyl
ether, polyoxyethylene lanoline/lanoline alcohol/beeswax
derivative, polyoxyethylene alkyl amine/fatty acid amide,
polyoxyethylene alkyl ether phosphoric acid/phosphate, and
high-molecular emulsifier.
[0028] In particular, the water-soluble base is preferably used.
The component in the water-soluble base includes, for example,
water, glycerin, propylene glycol or a mixture thereof, and
water-soluble gel having polyacrylate etc. added to such
material.
[0029] In addition, an adhesive used conventionally in a plaster
and tape can also be used as the base. The adhesive shall be
pharmacologically acceptable, and adhesives known in the art can be
used, and examples thereof include an acrylic adhesive,
rubber-based adhesive, silicon-based adhesive and urethane-based
adhesive. In particular, the acrylic adhesive and rubber-based
adhesive can be preferably used. These adhesives are in an
arbitrary state, for example in the form of a solution, emulsion,
hot-melt etc.
[0030] The acrylic adhesive includes, for example, adhesives
containing polyalkyl (meth) acrylate obtained by copolymerizing
alkyl (meth) acrylate as main component, and it may be a copolymer
of alkyl (meth) acrylate and a multifunctional monomer
copolymerizable therewith or other vinyl monomer.
[0031] The alkyl (meth) acrylate includes, for example, 2-ethylhexl
(meth) acrylate, dodecyl (meth) acrylate etc.
[0032] The multifunctional monomer includes, for example,
1,6-hexane glycol methacrylate, tetraethylene glycol diacrylate
etc., and the other vinyl monomer includes, for example,
N-vinyl-2-pyrrolidone, vinyl acetate etc.
[0033] The rubber-based adhesive includes adhesives based on
natural rubber, a styrene-isoprene-styrene block copolymer or a
styrene-olefin-styrene block copolymer, to which a tackifier such
as rosin, hydrogenated rosin, rosin ester, terpene resin, terpene
phenol resin, petroleum-based resin, coumarone resin, and
coumarone-indene resin is generally added.
[0034] A wide variety of other efficacious components may be added
if necessary to the dermal composition for external use of the
present invention. The efficacious components include, but are not
limited to, steroid anti-inflammatory agents, non-steroid
anti-inflammatory agents, anti-allergy agents, anti-histamine
agents, sterilizing agents, antibiotics, immunosuppressive agents
etc.
[0035] Inorganic fillers such as kaolin, bentonite, zinc oxide and
titanium oxide, viscosity regulators, antioxidants, pH adjusting
agents, buffers, preservatives and perfumes etc. may be added if
necessary to the dermal composition for external use of the present
invention.
[0036] The pH value of the dermal composition for external use of
the present invention is preferably 2 to 7. When the pH is 2 or
less, the skin to which it was applied may be irritated or
cromoglycic acid may be precipitated, while when the pH is higher
than 7, the stability of the monoester of polyvalent alcohol and
salicylic acid may be deteriorated. The pH is more preferably 4 to
5.
[0037] The method of producing the dermal composition for external
use of the present invention is not particularly limited, and there
is a method which involves kneading the above-mentioned sodium
cromoglycate, the monoester of polyvalent alcohol and salicylic
acid, etc., with the base.
[0038] The form of the dermal composition for external use of the
present invention is not particularly limited, and the composition
may be in such a state that the above sodium cromoglycate etc. are
dissolved in, or mixed and dispersed in, the base to form a cream,
paste, jelly, gel, emulsion or liquid (ointment, liniment, lotion
etc.); the above sodium cromoglycate etc. are dissolved in, or
mixed and dispersed in, the base and spread on a substrate
(poultice etc.); and the above sodium cromoglycate etc. are
dissolved in, or mixed and dispersed in, an adhesive as a base and
spread on a substrate (plaster, tape etc.).
[0039] When the substrate is used, the substrate can be suitably
selected depending on the form of the dermal composition for
external use, and it is preferably a flexible material through
which chemicals such as sodium cromoglycate do not permeate or
hardly permeate, and examples thereof include resin films made of
cellulose acetate, ethyl cellulose, polyethylene, polyvinyl
chloride, vinyl acetate-vinyl chloride copolymer, ethylene-vinyl
acetate copolymer, ethylene-vinyl acetate-carbon monoxide
copolymer, ethylene-butyl acrylate-carbon monoxide copolymer,
polyvinylidene chloride, polyurethane, nylon or polyethylene
terephthalate; aluminum sheets; woven fabrics; unwoven fabrics, and
laminated sheets thereof.
[0040] The dermal composition for external use of the present
invention exhibits the high therapeutic effect of sodium
cromoglycate by using sodium cromoglycate in combination with the
monoester of polyvalent alcohol and salicylic acid.
[0041] The dermal composition for external use of the present
invention is used for example as cosmetics, pharmaceutical
preparations etc. When the composition is used as cosmetics, it is
used as face lotion, milky lotion, facial pack etc. When the
composition is used as pharmaceutical preparations, it can be used
to treat various skin diseases such as rough dry skin, rash, heat
rash, sore, frostbite, diaper rash, atopic dermatitis, contact
dermatitis, seborrheic dermatitis, lichen simplex chronicus Vidal,
nummular eczema, housewife eczema, solar dermatitis, insect bite,
pruritus, prurigo, drug eruption, toxicoderma, psoriasis,
parapsoriasis, pustulosis palmaris et plantaris, lichen planus,
lichen nitidus, pityriasis rubra pilaris Devergie, pityriasis rosea
Gibert, erythema, erythrodermia, discoid lupus erythematosus,
systemic lupus erythematosus, pemphigus, pemphigoid, dermatitis
herpetiformis Duhring, alopecia areata, vitiligo vulgaris,
sarcoidosis, cutaneous amyloidosis, keloid, hypertrophic scar,
wound, bed sore, skin ulcer, loss of hair, etc.
[0042] The present invention also relates to a cosmetic which is
obtainable by using the dermal composition for external use of the
present invention and a pharmaceutical preparation which is
obtainable by using the dermal composition for external use of the
present invention.
[0043] The method for applying the dermal composition for external
use of the present invention is varied depending on the type of
disease, the severity of conditions, the size of an affected site,
but for example, the composition is applied once or several times
onto the affected site in an amount of 0.1 to 10 g per day.
BEST MODE FOR CARRYING OUT THE INVENTION
[0044] The present invention is described in more detail by
reference to the Examples, but the present invention is not limited
to the Examples.
EXAMPLES 1 TO 33 AND COMPARATIVE EXAMPLES 1 TO 16
[0045] The respective components shown in Tables 1 to 5 were
admixed in predetermined amounts (% by weight) to prepare a gel, a
cream or an ointment.
[0046] In Tables 1 to 5, the respective components are as
follows:
[0047] Sodium cromoglycate (DSCG manufactured by Fukuzyu
Pharmaceutical Co.,LTD.), glycol salicylate (trade name "Saliment",
SG manufactured by Yoshitomi Fine Chemicals,Ltd.), a hydrophilic
ointment (manufactured by Maruishi Pharmaceutical. Co., Ltd.),
white vaseline (manufactured by Maruishi Pharmaceutical. Co.,
Ltd.), stearyl alcohol (manufactured by Wako Pure Chemical
Industries, Ltd.), polyoxyethylene hydrogenated castor oil 60
(trade name "HCO-60", manufactured by Nikko Chemicals Co., Ltd.),
polyacrylate gel (trade name "Sintalen L", PA gel manufactured by
3V Sigma Chemical Co.), glycerin (manufactured by Maruishi
Pharmaceutical. Co., Ltd.), propylene glycol (PG manufactured by
Maruishi Pharmaceutical. Co., Ltd.), alginic acid propylene glycol
ester (APG manufactured by Kibun food chemifa Co., Ltd.), urea
(manufactured by Kozakai pharmaceutical Co., Ltd), sodium
hyaluronate (HA manufactured by Asahi Kasei Corporation), squalane
(manufactured by Maruha Corporation), salicylic acid (SA
manufactured by Wako Pure Chemical Industries, Ltd.), methyl
salicylate (SM manufactured by Wako Pure Chemical Industries,
Ltd.), lauric acid diethanol amide (LD manufactured by NOF
Corporation), triethanol amine (Nippon Shokubai Co., Ltd.) and
methyl p-oxybenzoate (Paraben manufactured by Yoshitomi Fine
Chemicals,Ltd.).
[0048] In the base in Tables 3 and 5, "vaseline etc." refers to a
mixture of white vaseline:stearyl alcohol:polyoxyethylene
hydrogenated castor oil 60=6:1:1 (ratio by weight ).
[0049] The gel, cream and ointment prepared in Examples 1 to 33 and
Comparative Examples 1 to 16 were used in Test Examples 1 to 6 and
evaluated for their effect.
[0050] The results are shown in Tables 1 to 5.
TEST EXAMPLE 1
Effect on Primary Irritative Skin Reaction Induced by
Dinitrochlorobenzene
[0051] Dorsal skin of a 7-week-old male Wister rat was shaved, and
20 .mu.L of 0.8% (w/v) 2,4-dinitrochlorobenzene (DNCB manufactured
by Wako Pure Chemical Industries, Ltd.) in acetone was dropped onto
the hair-shaved region and then dried.
[0052] Then, a circular polyethylene terephthalate/ethylene-vinyl
acetate laminate film having a radius of 1 cm was provided on the
polyethylene terephthalate side with 0.1 g of the gel, cream or
ointment, and then put on so as to bring this side into contact
with the hair-shaved region.
[0053] Twenty four hours thereafter, the film was released, and the
intensity of erythema (B) on the region was measured with a color
difference meter (CR-200 manufactured by Minolta). Separately, a
control agent (that is, a preparation wherein sodium cromoglycate
in the gel, cream or ointment was replaced by the same base
composition as in the original gel, cream or ointment) was used in
place of the gel, cream or ointment and measured in the same manner
for the intensity of erythema (A). From these results, the degree
of suppression was calculated from the following equation: Degree
of suppression (%)=((A)-(B))/(A).times.100
TEST EXAMPLE 2
Effect on Type IV Allergic Reaction (Skin Contact Hypersensitive
Reaction Induced by Dinitrochlorobenzene)
[0054] Abdominal skin of a 5-week-old male Wister rat was shaved,
and 20 .mu.L of 20% (w/v) 2,4-dinitrochlorobenzene in acetone was
dropped onto the hair-shaved region and then dried to sensitize the
skin. Two weeks after sensitization, dorsal skin of the rat was
shaved, and then, 20 .mu.L of 0.5% (w/v) 2,4-dinitrochlorobenzene
in acetone was dropped onto the hair-shaved region and thereafter,
dried to induce the reaction.
[0055] Then, a circular polyethylene terephthalate/ethylene-vinyl
acetate laminate film having a radius of 1 cm was provided on the
polyethylene terephthalate side with 0.1 g of the gel, cream or
ointment, and then put on so as to bring this side into contact
with the hair-shaved region of dorsal skin.
[0056] Twenty four hours after the film was put on, the film was
released, and the intensity of erythema (B) on the region was
measured with a color difference meter (CR-200 manufactured by
Minolta). Separately, the control agent in Test Example 1 was used
in place of the gel, cream or ointment and measured in the same
manner for the intensity of erythema (A). From these results, the
degree of suppression was calculated from the following equation:
Degree of suppression (%)=((A)-(B))/(A).times.100
TEST EXAMPLE 3
Effect on Type I Allergic Reaction (Homologous PCA Reaction for 48
Hours)
(1) Preparation of Rat anti-2,4-dinitrobenzenesulfonic
acid--Ascaris suum Extract (DNP-As) Serum
[0057] DNP-As was prepared according to a method of Tada and
Okumura (Journal of Immunology, 106, 1002, 1971). That is, an
extract of Ascaris suum was prepared according to a method of
Strejan and Campbell (Journal of Immunology, 98, 893, 1967) and
then bound to 2,4-dinitrobenzenesulfonic acid (DNP) by a method of
Eisen et al. (Journal of American Chemical Society, 75, 4583,
1953), whereby DNP-As was obtained.
[0058] One mg of DNP-As thus obtained was dissolved in 1 ml of
physiological saline containing 10.sup.10 of dead pertussis
bacteria floating therein, and then injected into the skin of the
extremities of a female rat weighing about 200 g. After 5 days, 0.5
mg of DNP-As was dissolved in 0.5 mL of physiological saline and
injected into the right and left dorsal muscles of the rat. Eight
days after the initial injection, blood was collected from the
aorta abdominals, and serum was separated to give rat anti-DNP-As
serum.
[0059] The titer of this antiserum in rat homologous PCA reaction
for 24 hours was 1:512.
(2) Effect on Rat Homologous PCA Reaction for 48 Hours
[0060] Dorsal skin of a 7-week-old male Wister rat was shaved, and
0.05 mL of rat anti-DNA-As serum diluted 100-fold with
physiological saline was administered intracutaneously for passive
sensitization. Immediately thereafter, a circular polyethylene
terephthalate/ethylene-vinyl acetate laminate film having a radius
of 1 cm was provided on the polyethylene terephthalate side with
0.1 g of the gel, cream or ointment, and then put on so as to bring
this side into contact with the hair-shaved region. Twenty hours
after sensitization, the gel, cream or ointment was put on in the
same manner. Twenty four hours after sensitization, the film was
released, and 2.5 mL/kg of 0.5% Evans Blue (manufactured by Merck
Ltd.) in physiological saline containing 2 mg/mL of DNP-As as the
corresponding antigen was intravenously administered to induce PCA
reaction.
[0061] The pigment leakage from the site where the intradermal
reaction had been induced was extracted and quantified according to
a method of Harada et al. (J. Pharm. Pharmacol., 23, 218, 1971).
That is, the animal was sacrificed 1 hour after injection of the
antigen, and the skin in the PCA reaction site was cut thin and
dipped for 24 hours in a mixed solution consisting of 0.3% aqueous
sodium sulfate and acetone in a volume ratio 3:7 to determine the
amount of the pigment leakage (B). As the control in this test, the
control agent in Test Example 1 was used to determine the amount of
the pigment leakage (A) in the same manner. From these results, the
degree of suppression was calculated from the equation below:
Degree of suppression (%)=((A)-(B))/(A).times.100
TEXT EXAMPLE 4
Effect on a Rat Dry Skin Model by Using N-lauroyl
sarcosine-dinitrochlorobenzene
[0062] N-lauroyl sarcosine (manufactured by Nacalai Tesque, Inc.)
and gelled hydrocarbons (trade name "Plastibase", manufactured by
Bristol-Myers Squibb) were fed in a weight ratio of 2:98 to a
mortar and kneaded until the mixture was uniform as a whole to give
an ointment (referred to hereinafter as Plastibase ointment
containing 2% LS).
[0063] Dorsal skin of a 7-week-old male Wister rat was shaved, and
a circular polyethylene terephthalate/ethylene-vinyl acetate
laminate film having a radius of 1 cm was provided on the
polyethylene terephthalate side with 0.1 g of Plastibase ointment
containing 2% LS, and then put on so as to bring this side into
contact with the hair-shaved region.
[0064] Twenty four hours thereafter, the film was released, and 20
.mu.L of 1% (w/v) 2,4-dinitrochlorobenzene in acetone was applied
onto this site and then well dried. Immediately after drying, a
circular polyethylene terephthalate/ethylene-vinyl acetate laminate
film having a radius of 1 cm was provided on the polyethylene
terephthalate side with 0.1 g of the gel, cream or ointment, and
then put on so as to bring this side into contact with the
hair-shaved region.
[0065] Eighteen hours after the film was put on, the firm was
released, and 6 hours thereafter, the transepidermal water loss
(TEWL) in the site was measured with EVAPORIMETER EP1 (manufactured
by Servomed Co.,). Lower TEWL is indicative of a higher therapeutic
effect on dry skin. Separately, the ointment base (Plastibase) only
was used as the control in place of the gel, cream or ointment and
examined in the same manner. The normal rat skin (skin onto which
neither Plastibase ointment containing 2% LS nor the DNCB solution
in acetone had been applied), without previously sticking thereon
or after sticking only the ointment base (Plastibase) thereon for
24 hours was measured for TEWL in the same manner.
TEST EXAMPLE 5
Effect on a Rat Model with Reduction in Skin Barrier Functions by
Using N-lauroyl sarcosine-dinitrochlorobenzene
[0066] Crystal Violet (manufactured by Wako Pure Chemical
Industries, Ltd.) and a hydrophilic ointment were fed in a weight
ratio of 1:99 to a mortar and kneaded until the mixture was uniform
as a whole to give an ointment (referred to hereinafter as the
hydrophilic ointment containing 1% CV).
[0067] Dorsal skin of a 7-week-old male Wister rat was shaved, and
a circular polyethylene terephthalate/ethylene-vinyl acetate
laminate film having a radius of 1 cm was provided on the
polyethylene terephthalate side with 0.1 g of Plastibase ointment
containing 2% LS, and then put on so as to bring this side into
contact with the hair-shaved region.
[0068] Twenty four hours after the film was put on, the film was
released, and 20 .mu.L of 1% (w/v) 2,4-dinitrochlorobenzene in
acetone was applied onto this site and then well dried. Immediately
after drying, a circular polyethylene terephthalate/ethylene-vinyl
acetate laminate film having a radius of 1 cm was provided on the
polyethylene terephthalate side with 0.1 g of the gel, cream or
ointment, and then put on so as to bring this side into contact
with the hair-shaved region.
[0069] Twenty four hours after the film was put on, the film was
released, and a circular polyethylene terephthalate/ethylene-vinyl
acetate laminate film having a radius of 1 cm was provided on 0.05
g of the hydrophilic ointment containing 1% CV, and then put on so
as to bring this side into contact with the hair-shaved region.
[0070] Twenty four hours after the film was put on, the film was
released, and the hair-shaved region was subjected to 8 times of
tape stripping with a cellophane tape (manufactured by Sekisui
Chemical Co., Ltd.) to remove its keratin layer, and the bluing
degree of that site (B) was measured with a color difference meter.
As the control in this test, the control agent in Test Example 1
was used to determine bluing degree (A) in the same manner. From
these results, the degree of suppression was calculated from the
equation below. A higher bluing degree indicates a higher amount of
Crystal Violet entering the epidermal layer, thus showing a
reduction in skin barrier functions, and suppression of the bluing
degree indicates that skin barrier functions are improved, that is,
the skin is kept in a healthy condition. Degree of suppression
(%)=((A)-(B))/(A).times.100
TEST EXAMPLE 6
[0071] The preparations in Examples 28 to 33 were stored at
60.degree. C. for 4 weeks, and before and after storage, the
concentrations of sodium cromoglycate and glycol salicylate in the
preparations were measured by high performance liquid
chromatography. TABLE-US-00001 TABLE 1 Composition (% by weight)
Transcutaneous absorption Base enhancer Preservative DSCG SG Water
PA gel APG Glycerin PG Urea HA Paraben Example 1 5 15 25 0 0 30 25
0 0 0 Example 2 5 15 20 0 0 30 25 5 0 0 Example 3 5 15 24.8 0 0 30
25 0 0.2 0 Example 4 5 15 24 1 0 30 25 0 0 0 Example 5 5 15 19 1 0
30 25 5 0 0 Example 6 5 15 23.8 1 0 30 25 0 0.2 0 Example 7 5 15
23.5 1 0 30 25 0 0 0.5 Example 8 5 15 23.3 1 0 30 25 0 0.2 0.5
Example 9 5 15 22.5 1 1 30 25 0 0 0.5 Example 10 5 15 22.3 1 1 30
25 0 0.2 0.5 Evaluation Test Test Test Test Example 1 Example 2
Example 3 Test Example 5 degree of degree of degree of Example 4
degree of suppression suppression suppression TEWL suppression (%)
(%) (%) (g/m.sup.2 h) (%) Example 1 70.1 66.0 25 7 68.2 Example 2
71.8 69.1 28.9 6 70.1 Example 3 72.9 69.5 29.2 6 70.5 Example 4
70.3 65.8 24.8 7 69.0 Example 5 72.1 69.0 29.5 6 70.5 Example 6
73.0 70.1 29.1 6 71.1 Example 7 73.0 70.0 30.0 6 70.8 Example 8
72.9 73.2 30.3 6 71.5 Example 9 73.3 73.0 30.5 6 71.6 Example 10
73.5 73.5 30.8 6 72.0
[0072] TABLE-US-00002 TABLE 2 Composition (% by weight) Evaluation
Test Example 1 Base degree of Test Example 4 Hydrophilic
Transcutaneous absorption enhancer suppression TEWL DSCG SG
ointment Glycerin PG Urea HA Squalane (%) (g/m.sup.2 h) Example 11
5 15 80 0 0 0 0 0 41.2 14 Example 12 5 15 50 30 0 0 0 0 51.3 10
Example 13 5 15 50 0 30 0 0 0 50 11 Example 14 5 15 75 0 0 5 0 0
50.9 10 Example 15 5 15 79.8 0 0 0 0.2 0 49.6 9 Example 16 5 15 65
0 0 0 0 15 49.6 11 Example 17 5 15 35 30 0 0 0 15 63 7 Example 18 5
15 30 30 0 5 0 15 65.1 7 Example 19 5 15 30 0 30 5 0 15 62.7 8
[0073] TABLE-US-00003 TABLE 3 Composition (% by weight) Evaluation
Test Example 1 Test degree of Example 4 Base Transcutaneous
absorption enhancer suppression TEWL DSCG SG Vaseline etc. Water
Glycerin PG Urea HA Squalane (%) (g/m.sup.2 h) Example 20 5 15 40
40.0 0 0 0 0 0 40.1 16 Example 21 5 15 40 30.0 10 0 0 0 0 48.6 12
Example 22 5 15 40 30.0 0 10 0 0 0 47.9 12 Example 23 5 15 40 35.0
0 0 5 0 0 47.0 12 Example 24 5 15 40 39.8 0 0 0 0.2 0 46.0 11
Example 25 5 15 40 25.0 0 0 0 0 15 46.5 13 Example 26 5 15 40 10.0
10 0 5 0 15 62.9 8 Example 27 5 15 40 10.0 0 10 5 0 15 61.0 10
[0074] TABLE-US-00004 TABLE 4 Composition (% by weight)
Transcutaneous Base absorption enhancer Preservative pH adjusting
agent DSCG SG Water PA gel Glycerin PG HA Paraben Triethanol amine
Example 28 5 15 23.5 1 30 25 0 0.5 Optimal amount Example 29 5 15
23.5 1 30 25 0 0.5 Optimal amount Example 30 5 15 23.5 1 30 25 0
0.5 Optimal amount Example 31 5 15 23.3 1 30 25 0.2 0.5 Optimal
amount Example 32 5 15 23.3 1 30 25 0.2 0.5 Optimal amount Example
33 5 15 23.3 1 30 25 0.2 0.5 Optimal amount Evaluation Test Example
1 Test Example 6 degree of Test Example 4 Residual degree
suppression TEWL (%) pH (%) (g/m.sup.2 h) DSCG SG Example 28 4.0
71.8 6 99.5 98.7 Example 29 4.5 72.1 6 99.6 98.4 Example 30 5.0
72.0 6 99.2 98.0 Example 31 4.0 72.8 6 99.6 98.9 Example 32 4.5
72.9 6 99.6 98.5 Example 33 5.0 73.1 6 99.3 98.0
[0075] TABLE-US-00005 TABLE 5 Composition (% by weight) Base
Transcutaneous Hydrophilic Vaseline absorption enhancer
Preservative DSCG SA SM ointment etc. Water PA gel LD Glycerin PG
Squalane Urea Paraben Comparative 5 0 0 0 0 95 0 0 0 0 0 0 0
Example 1 Comparative 5 15 0 0 0 79 1 0 0 0 0 0 0 Example 2
Comparative 5 0 15 0 0 79 1 0 0 0 0 0 0 Example 3 Comparative 5 0 0
0 0 38.5 1 0 30 25 0 0 0.5 Example 4 Comparative 5 15 0 0 0 23.5 1
0 30 25 0 0 0.5 Example 5 Comparative 5 0 15 0 0 23.5 1 0 30 25 0 0
0.5 Example 6 Comparative 5 0 0 95 0 0 0 0 0 0 0 0 0 Example 7
Comparative 5 15 0 80 0 0 0 0 0 0 0 0 0 Example 8 Comparative 5 0
15 80 0 0 0 0 0 0 0 0 0 Example 9 Comparative 5 0 0 50 0 0 0 0 30 0
15 0 0 Example 10 Comparative 5 15 0 35 0 0 0 0 30 0 15 0 0 Example
11 Comparative 5 0 15 35 0 0 0 0 30 0 15 0 0 Example 12 Comparative
5 0 0 0 40 55 0 0 0 0 0 0 0 Example 13 Comparative 5 15 0 0 40 40 0
0 0 0 0 0 0 Example 14 Comparative 5 0 15 0 40 40 0 0 0 0 0 0 0
Example 15 Comparative 5 0 0 0 0 42 1 2 30 0 0 20 0 Example 16
Control With the ointment base (Plastibase) stuck thereon Normal
skin With nothing stuck thereon Normal skin With the ointment base
(Plastibase) stuck thereon Evaluation Test Test Test Example 1
Example 2 Example 3 Test degree of degree of degree of Example 4
suppression suppression suppression TEWL (%) (%) (%) (g/m.sup.2 h)
Comparative 4.8 4.5 2.0 39 Example 1 Comparative 4.5 4.6 2.2 40
Example 2 Comparative 4.5 4.3 2.4 40 Example 3 Comparative 4.3 4.5
2.2 38 Example 4 Comparative 4.7 4.0 2.2 37 Example 5 Comparative
4.7 4.1 1.8 38 Example 6 Comparative 5.0 4.2 1.9 39 Example 7
Comparative 4.8 3.9 2.3 40 Example 8 Comparative 4.8 4.0 2.0 40
Example 9 Comparative 4.0 4.0 2.4 41 Example 10 Comparative 4.4 4.0
2.1 39 Example 11 Comparative 4.3 3.8 1.6 40 Example 12 Comparative
4.6 3.8 2.0 39 Example 13 Comparative 3.9 3.9 2.5 41 Example 14
Comparative 3.9 3.9 2.1 40 Example 15 Comparative 29.4 26.8 8.7 18
Example 16 Control -- -- -- 41 Normal skin -- -- -- 3 Normal skin
-- -- -- 4
[0076] From the results of the degree of suppression in Test
Example 1 shown in Tables 1 to 5, it was found that the dermal
composition for external use of the present invention demonstrates
a sufficient effect in treatment of the skin inflammation. From the
results of the degree of suppression in Test Example 2 shown in
Tables 1 and 5, it was found that the dermal composition for
external use of the present invention demonstrates a sufficient
effect in treatment of the skin inflammation in which type IV
allergy is involved. From the results of the degree of suppression
in Test Example 3 shown in Tables 1 and 5, it was found that the
dermal composition for external use of the present invention
demonstrates a sufficient effect in treatment of the skin
inflammation in which type I allergy is involved. From the TEWL
values in Test Example 4 shown in Tables 1 to 5, it was found that
the dermal composition for external use of the present invention
demonstrates a sufficient effect in treatment of dry skin. From the
results of the degree of suppression in Test Example 5 shown in
Table 1, it was found that the dermal composition for external use
of the present invention has an effect of improving the skin
barrier functions. From the results in Test Example 6 shown in
Table 4, it was found that the dermal composition for external use
of the present invention exhibits sufficient shelf stability.
INDUSTRIAL APPLICABILITY
[0077] According to the present invention, there can be provided a
dermal composition for external use which keeps the skin healthy
and demonstrates a sufficient effect in treating skin diseases.
* * * * *